Killert Cells News Today

Researchers have identified fragments from influenza B viruses that the immune system consistently recognise, offering promising targets for a universal influenza B vaccine.

CON-CRĒT by Vireo Systems now holds the patent for research supporting creatine’s ability to help the body fight off coronavirus and influenza A.

CON-CRĒT by Vireo Systems now holds the patent for research supporting creatine’s ability to help the body fight off coronavirus and influenza A.

Killer T cells in older adults, directed against influenza viruses, closely resemble those found in newborns and children, but struggle to recognise infected cells.

T cells recognize and kill cancer cells but quickly lose their effectiveness. This fast dysfunction may help explain why immunotherapy doesn’t lead to long-term remission for many patients.

These multipronged T-cells could be levereged in novel therapies that make our immune system more effective at killing cancer.

Tevogen Bio Inc. (“Tevogen Bio”) is an advanced-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell...

FinancialContent fully hosted finance channel

Immunotherapy has the potential to eliminate tumors, but works best for select patients. Engineering T cells to bypass cancer’s defenses could help expand treatment eligibility to more patients.

A new study describes rogue killer T cells as “rogue immune cells” to be one of the causes of autoimmune diseases.